Osteoporosis, introduced by Pommer in 1885, is a systemic disease characterized by a decrease in bone mass and microstructural degeneration of bone, resulting in increased bone fragility and susceptibility to fracture. Osteoporosis can be divided into three categories: the first category is primary osteoporosis, which is a physiological degenerative disease that inevitably occurs with age; the second category is secondary osteoporosis, which is induced by some factors such as other diseases or drugs. The third category is idiopathic osteoporosis, mostly seen in adolescents or adults aged 8-14 years, mostly with a genetic family history, more women than men; osteoporosis occurring in pregnant women and lactating women is also included in idiopathic osteoporosis. Among them, primary osteoporosis can be divided into two types: Type I is postmenopausal osteoporosis, which is high conversion osteoporosis; Type II is senile osteoporosis, which is low conversion osteoporosis. Deng Weimin, Department of Traditional Chinese Medicine, Guangzhou General Hospital, Guangzhou Military Region When formulating treatment plans for patients with osteoporosis, it is important to first understand the occurrence, development The treatment plan for osteoporosis patients must first understand the occurrence, development and attribution of osteoporosis, and develop an effective and feasible individualized treatment plan for different patients. The goals of osteoporosis treatment are to reduce bone mass lesions, relieve skeletal pain, and reduce the incidence of fractures. The main therapeutic drugs for osteoporosis include those that promote bone mineralization by replenishing trace elements needed for bone, such as calcium and vitamin D; those that reduce the level of bone resorption by inhibiting the activity of osteoblasts; and those that reduce the level of bone resorption by inhibiting the activity of osteoclasts. The main therapeutic drugs for osteoporosis include those that promote bone mineralization by replenishing trace elements needed for bone, such as calcium and vitamin D; those that reduce bone resorption by inhibiting osteoclast activity, such as estrogen, bisphosphonates, and calcitonin; and those that increase bone formation by promoting osteoblast activity, such as fluoride and parathyroid hormone (PTH). The selection and application varies for different clinical types of osteoporosis. Among them, “pro-new bone ” is a treatment method that stimulates new bone production by promoting the proliferation and activity of osteoblasts or enhancing the recruitment and differentiation of osteoblasts through the action of drugs on osteoblasts, thus achieving the purpose of enhancing the level of osteogenesis, increasing bone mass and relieving various symptoms of osteoporosis. It is indicated for male and female patients who are at high risk of future osteoporosis-related fractures, including patients with clinically or imaging diagnosed vertebral compression fractures and other osteoporosis-related fractures, patients with bone mineral density (BMD) within the diagnostic range of osteoporosis, or patients with very low BMD (T-value ≤ -3) even though no fracture has yet occurred. In addition, this therapy is also indicated for patients who have been previously treated with antiresorptive medications with poor results, i.e., patients who have sustained fractures or rapid and substantial bone loss during treatment, or who have been unable to prevent ongoing bone loss with conventional therapy. Due to its unique mechanism of action, parathyroid hormone (PTH) is currently the only recognized bone anabolic therapy that can increase bone mass (especially in the spine) more significantly than other anti-bone resorption treatments.PTH first promotes bone formation and then subsequently promotes both bone formation and bone resorption, with stimulation of bone formation being the mainstay. The new bone produced by PTH restores bone microarchitecture, including improved trabecular coherence and increased cortical bone thickness. In addition, bone formation can also be induced at the periosteal surface and may affect the size and shape of the bone, although this has not been fully demonstrated, but it certainly has an additional positive effect on bone strength. It is important to note that, despite the remarkable efficacy of PTH in the treatment of osteoporosis, it is not suitable for patients with a high risk of osteosarcoma, a history of Paget’s disease, unexplained alkaline phosphatase elevations, children, and adults who present with non-ossification of the epiphysis.